InVivo names new CEO
This article was originally published in Scrip
Cambridge, Massachusetts-based InVivo Therapeutics has named Mark Perrin chief executive officer – effective 6 January 2014. Upon his appointment, Mr Perrin will also become a member of the company's board of directors. Prior to joining the company – which specializes in drug delivery technologies with on spinal cord injuries – Mr Perrin was president of Dennan Consulting, a biotech consulting firm. Meanwhile, InVivo has also promoted Lisa Crockett to vice-president, regulatory and Kristin Neff to vice-president, clinical operations – effective from the 1 January 2014.